Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | MYC | P01106 | 1/20 | 0.30 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19259619 | 0.75 | MAOA (0.47) | KDM4EALDH1A1MAPTNPSR1L3MBTL1 | |
| SCHEMBL19259805 | 0.69 | FBP1 (0.42) | PDE7A | |
| SCHEMBL29543575 | 0.69 | LMNA (0.57) | LMNAPDE7AALDH1A1MAPTNPSR1 | |
| SCHEMBL3282096 | 0.69 | LMNA (0.57) | LMNAPDE7AALDH1A1MAPTNPSR1 | |
| SCHEMBL19259622 | 0.66 | HTR6 (0.41) | LMNAKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL19259600 | 0.66 | CYP3A4 (0.45) | PDE7AKDM4EALDH1A1MAPTCYP1A2 | |
| SCHEMBL19259881 | 0.66 | MAOA (0.52) | KDM4EALDH1A1MAPTNPSR1L3MBTL1 | |
| SCHEMBL19274416 | 0.65 | KDM4E (0.42) | KDM4EMAPTNPSR1L3MBTL1MAOA | |
| SCHEMBL2768615 | 0.64 | CA12 (0.50) | LMNAALDH1A1L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL25142154 | 0.64 | MYC (0.40) | LMNAPDE7AALDH1A1MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416956-B1 | METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-24 | — | — | US | disclosed |
| CN-109311839-B | Methylamine derivatives as lysyl oxidase inhibitors for the treatment of cancer | 癌症研究协会皇家癌症医院 | 2021-11-02 | — | — | CN | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-20 | — | — | US | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | LMNA 887/4885PDE7A 4438/4885KDM4E 142/4885 |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | LMNA 887/4885PDE7A 4438/4885KDM4E 142/4885 |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | LMNA 887/4885PDE7A 4438/4885KDM4E 142/4885 |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | LMNA 887/4885PDE7A 4438/4885KDM4E 142/4885 |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | LMNA 887/4885PDE7A 4438/4885KDM4E 142/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | LMNA 887/4885PDE7A 4438/4885KDM4E 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.